Full Disclosure Policy Affecting CE Activities:
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:
Andrea S. Franks, PharmD, BCPS
Associate Professor and Director of Education
College of Pharmacy, Knoxville Campus
University of Tennessee
• Dr Franks reports having no significant financial or advisory relationships with corporate organizations related to this activity.
Christina Barrington, PharmD
Health Alliance Medical Plans
• Dr Barrington reports having contracting or consulting arrangements with AstraZeneca, GlaxoSmithKline, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pfizer Global Pharmaceuticals, Proctor & Gamble Pharmaceuticals, Sanofi-Aventis, Santarus, Inc, Schering-Plough Corporation, Takeda Pharmaceuticals North America, Inc, and Teva Pharmaceuticals.
Mary Beth O'Connell, PharmD, BCPS, FASHP, FCCP
Department of Pharmacy Practice
Eugene Applebaum College of Pharmacy and Health Sciences
• Dr O'Connell reports receiving investigator-initiated sponsored grants from Merck & Co, Inc; serving on CE programs for Prime Pharmaceuticals, LTD; and participating in home study/live CE programs (book editor and midyear meeting) for the American Society of Health-System Pharmacists.
These potential conflicts have been reviewed and resolved by the Course Director and Associate Dean for Continuing Education.
Elena M. Umland, PharmD
Associate Dean for Academic Affairs
Jefferson College of Health Professions
Jefferson School of Pharmacy
Thomas Jefferson University
• Dr Umland reports having no significant financial or advisory relationships with corporate organizations related to this activity.
Notice: In accordance with ACPE Criteria for Quality, the audience is advised that an article in this CE activity contains reference(s) to unlabeled or unapproved uses of drugs or devices.
Dr O'Connell 1-84 parathyroid hormone, 3-34 amino acid, alfacalcidol, aVb3 integrin inhibitors, anti-sclerostin monoclonal antibodies, antitumor necrosis factor agents, arzoxifene, balicatib, bazedoxifene, conjugated equine estrogens with trimegestone or bazedoxifene, denosumab, growth hormone, interleukin-1 receptor antagonists, lasofoxifene, new formulations of parathyroid hormone, nitroglycerin, odanacatib, ospemifene, parathyroid hormone-related protein, relacatib, strontium ranelate, testosterone, toremifene, vitamin K, and zoledronic acid.
All other faculty have indicated that they have not referenced unlabeled or unapproved uses of drugs or devices.
University of Tennessee Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. University of Tennessee Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.